Latest Vioxx verdict is win number five for Merck

Share this article:
Merck has been cleared of responsibility in the heart attack of a former Vioxx patient in the 10th case to go to trial over the withdrawn painkiller. The latest verdict brings the trial tally to five wins and four losses for Merck. A new trial was granted for the remaining verdict in New Jersey last month, following the emergence of new data in that case. In the latest case, a federal jury in New Orleans ruled Merck had adequately warned of Vioxx’s heart risks and stated that Vioxx wasn’t the cause of the heart attack of Robert Smith, 56, of Florence, KY. Merck withdrew Vioxx from the market after a study linked the drug to heart risks two years ago this week.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.